Probiogen Signs Therapeutic Protein Process Development Contract with Virdante

ProBioGen, a technology and service provider for the development and production of biopharmaceutical drug substances, has announced the signing of a contract with Virdante Biopharmaceuticals, a US-based biopharmaceutical development company.

The former will contribute producer cell line development and process engineering for one of the latter’s proprietary therapeutic proteins. The latter’s protein products incorporate the company’s proprietary “Sialic Switch” technology that improves the anti-inflammatory properties of an antibody for autoimmune and inflammatory diseases. Virdante selected ProBioGen for its expertise in developing royalty-free pharmaceutical cell lines and robust, economical processes for Good Manufacturing Practice (GMP)-manufacturing.